GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    NEOTROPICAL ALIEN MAMMALS: a data set of occurrence and abundance of alien mammals in the Neotropics
    Wiley ; 2020
    In:  Ecology Vol. 101, No. 11 ( 2020-11)
    Details
    In: Ecology, Wiley, Vol. 101, No. 11 ( 2020-11)
    Abstract: Biological invasion is one of the main threats to native biodiversity. For a species to become invasive, it must be voluntarily or involuntarily introduced by humans into a nonnative habitat. Mammals were among first taxa to be introduced worldwide for game, meat, and labor, yet the number of species introduced in the Neotropics remains unknown. In this data set, we make available occurrence and abundance data on mammal species that (1) transposed a geographical barrier and (2) were voluntarily or involuntarily introduced by humans into the Neotropics. Our data set is composed of 73,738 historical and current georeferenced records on alien mammal species of which around 96% correspond to occurrence data on 77 species belonging to eight orders and 26 families. Data cover 26 continental countries in the Neotropics, ranging from Mexico and its frontier regions (southern Florida and coastal‐central Florida in the southeast United States) to Argentina, Paraguay, Chile, and Uruguay, and the 13 countries of Caribbean islands. Our data set also includes neotropical species (e.g., Callithrix sp., Myocastor coypus , Nasua nasua) considered alien in particular areas of Neotropics. The most numerous species in terms of records are from Bos sp. ( n = 37,782), Sus scrofa ( n = 6,730), and Canis familiaris ( n = 10,084); 17 species were represented by only one record (e.g., S yncerus caffer, Cervus timorensis, Cervus unicolor, Canis latrans ). Primates have the highest number of species in the data set ( n = 20 species), partly because of uncertainties regarding taxonomic identification of the genera Callithrix, which includes the species Callithrix aurita, Callithrix flaviceps, Callithrix geoffroyi, Callithrix jacchus, Callithrix kuhlii, Callithrix penicillata , and their hybrids. This unique data set will be a valuable source of information on invasion risk assessments, biodiversity redistribution and conservation‐related research. There are no copyright restrictions. Please cite this data paper when using the data in publications. We also request that researchers and teachers inform us on how they are using the data.
    Type of Medium: Online Resource
    ISSN: 0012-9658 , 1939-9170
    URL: Issue
    URL: Article
    DOI: 10.1002/ecy.v101.11
    DOI: 10.1002/ecy.3115
    RVK:
    WA 15000
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1797-8
    detail.hit.zdb_id: 2010140-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    NEOTROPICAL XENARTHRANS: a data set of occurrence of xenarthran species in the Neotropics
    Wiley ; 2019
    In:  Ecology Vol. 100, No. 7 ( 2019-07)
    Details
    In: Ecology, Wiley, Vol. 100, No. 7 ( 2019-07)
    Abstract: Xenarthrans—anteaters, sloths, and armadillos—have essential functions for ecosystem maintenance, such as insect control and nutrient cycling, playing key roles as ecosystem engineers. Because of habitat loss and fragmentation, hunting pressure, and conflicts with domestic dogs, these species have been threatened locally, regionally, or even across their full distribution ranges. The Neotropics harbor 21 species of armadillos, 10 anteaters, and 6 sloths. Our data set includes the families Chlamyphoridae (13), Dasypodidae (7), Myrmecophagidae (3), Bradypodidae (4), and Megalonychidae (2). We have no occurrence data on Dasypus pilosus (Dasypodidae). Regarding Cyclopedidae, until recently, only one species was recognized, but new genetic studies have revealed that the group is represented by seven species. In this data paper, we compiled a total of 42,528 records of 31 species, represented by occurrence and quantitative data, totaling 24,847 unique georeferenced records. The geographic range is from the southern United States, Mexico, and Caribbean countries at the northern portion of the Neotropics, to the austral distribution in Argentina, Paraguay, Chile, and Uruguay. Regarding anteaters, Myrmecophaga tridactyla has the most records ( n  = 5,941), and Cyclopes sp. have the fewest ( n  = 240). The armadillo species with the most data is Dasypus novemcinctus ( n  = 11,588), and the fewest data are recorded for Calyptophractus retusus ( n  = 33). With regard to sloth species, Bradypus variegatus has the most records ( n  = 962), and Bradypus pygmaeus has the fewest ( n  = 12). Our main objective with Neotropical Xenarthrans is to make occurrence and quantitative data available to facilitate more ecological research, particularly if we integrate the xenarthran data with other data sets of Neotropical Series that will become available very soon (i.e., Neotropical Carnivores, Neotropical Invasive Mammals, and Neotropical Hunters and Dogs). Therefore, studies on trophic cascades, hunting pressure, habitat loss, fragmentation effects, species invasion, and climate change effects will be possible with the Neotropical Xenarthrans data set. Please cite this data paper when using its data in publications. We also request that researchers and teachers inform us of how they are using these data.
    Type of Medium: Online Resource
    ISSN: 0012-9658 , 1939-9170
    URL: Issue
    URL: Article
    DOI: 10.1002/ecy.2019.100.issue-7
    DOI: 10.1002/ecy.2663
    RVK:
    WA 15000
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 1797-8
    detail.hit.zdb_id: 2010140-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients
    Wiley ; 2014
    In:  Arthritis & Rheumatology Vol. 66, No. 6 ( 2014-06), p. 1659-1665
    Details
    In: Arthritis & Rheumatology, Wiley, Vol. 66, No. 6 ( 2014-06), p. 1659-1665
    Abstract: Adult‐onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and in small series of patients with AOSD. The aim of this multicenter study was to assess the efficacy of TCZ in patients with AOSD refractory to conventional treatment. Methods This was a retrospective open‐label study of TCZ treatment in 34 patients with AOSD who had experienced an inadequate response to corticosteroids and at least 1 standard synthetic immunosuppressive drug and also, in many cases, biologic agents. Results The mean ± SD age of the patients (8 men and 26 women) was 38.7 ± 16.1 years. The median duration of AOSD before TCZ was initiated was 4.2 years (interquartile range [IQR] 1–9 years). The initial dosages of intravenous TCZ were 8 mg/kg every 4 weeks in 22 patients, 4 mg/kg every 4 weeks in 2 patients, and 8 mg/kg every 2 weeks in 10 patients. TCZ treatment resulted in rapid and maintained improvement in both clinical and laboratory parameters. After 1 year of TCZ therapy, the incidence of joint manifestations had decreased from 97.1% at baseline to 32.4%, the incidence of both cutaneous manifestations and fever had decreased from 58.8% to 5.9%, and the incidence of lymphadenopathy had decreased from 29.4% to 0%. A dramatic reduction in laboratory markers of inflammation, including the C‐reactive protein level, the erythrocyte sedimentation rate, and the ferritin level, was achieved. The median dosage of prednisone was also reduced, from 13.8 mg/day (IQR 5–45) at the initiation of TCZ to 2.5 mg/day (IQR 0–30) at 12 months. After a median followup of 19 months (IQR 12–31 months), only 2 patients required permanent discontinuation of TCZ therapy because of severe infections. Conclusion TCZ treatment was associated with rapid and maintained clinical and laboratory improvement in patients with AOSD refractory to standard treatment. However, joint manifestations seem to be more refractory to treatment compared with systemic manifestations.
    Type of Medium: Online Resource
    ISSN: 2326-5191 , 2326-5205
    URL: Issue
    URL: Article
    DOI: 10.1002/art.v66.6
    DOI: 10.1002/art.38398
    RVK:
    XA 10000
    RVK:
    XA 30325
    Language: English
    Publisher: Wiley
    Publication Date: 2014
    detail.hit.zdb_id: 2754614-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Brief Report: Association of HLA–DRB1*01 With IgA Vasculitis (Henoch‐Schönlein)
    Wiley ; 2015
    In:  Arthritis & Rheumatology Vol. 67, No. 3 ( 2015-03), p. 823-827
    Details
    In: Arthritis & Rheumatology, Wiley, Vol. 67, No. 3 ( 2015-03), p. 823-827
    Abstract: IgA vasculitis (Henoch‐Schönlein) (IgAV), formerly called Henoch‐Schönlein purpura, is the most common vasculitis in children, but it is not rare in adults. Increased familial occurrence supports a genetic predisposition to IgAV. In this context, an association with the HLA–DRB1*01 phenotype has been suggested in Caucasian individuals with IgAV. However, data on the potential association of IgAV with HLA–DRB1*01 were based on small case series. We undertook this study to further investigate this potential association by performing HLA–DRB1 genotyping in the largest series of IgAV patients ever assessed for genetic studies in Caucasians. Methods We assessed 342 Spanish patients with IgAV as well as 303 controls matched for sex and ethnicity. IgAV patients were required to fulfill the classification criteria described by Michel et al as well as the American College of Rheumatology 1990 classification criteria. HLA–DRB1 alleles were determined using the polymerase chain reaction–sequence‐specific oligonucleotide probe method. Results We found a statistically significant increase in the frequency of the HLA–DRB1*01 phenotype in IgAV patients compared with controls (43% versus 27%; P 〈 0.001) (odds ratio 2.03 [95% confidence interval 1.43–2.87]). This was due to the increased frequency of the HLA–DRB1*0103 allele in IgAV patients compared with controls (14.3% versus 2.0%; P 〈 0.001) (odds ratio 8.27 [95% confidence interval 3.46–23.9]). These results remained statistically significant after Bonferroni adjustment. In contrast, a statistically significant decrease in the frequency of the HLA–DRB1*03 phenotype, due to the presence of the HLA–DRB1*0301 allele, was observed in IgAV patients compared with controls (5.6% versus 18.2%; P 〈 0.001) (odds ratio 0.26 [95% confidence interval 0.14–0.47]), even after Bonferroni adjustment. No association of HLA–DRB1 with specific features of the disease was found. Conclusion Our study confirms an association of IgAV with HLA–DRB1*01 in Caucasians. There also appears to be a protective effect against the development of IgAV in Caucasians carrying the HLA–DRB1*03 phenotype.
    Type of Medium: Online Resource
    ISSN: 2326-5191 , 2326-5205
    URL: Issue
    URL: Article
    DOI: 10.1002/art.v67.3
    DOI: 10.1002/art.38979
    RVK:
    XA 10000
    RVK:
    XA 30325
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2754614-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
    Wiley ; 2019
    In:  Arthritis & Rheumatology Vol. 71, No. 12 ( 2019-12), p. 2081-2089
    Details
    In: Arthritis & Rheumatology, Wiley, Vol. 71, No. 12 ( 2019-12), p. 2081-2089
    Abstract: To compare the efficacy of infliximab ( IFX ) versus adalimumab ( ADA ) as a first‐line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease ( BD ). Methods We conducted an open‐label multicenter study of IFX versus ADA for BD ‐related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first‐line biologic agent based on physician and patient agreement. Patients received 3–5 mg/kg intravenous IFX at 0, 2, and 6 weeks and every 4–8 weeks thereafter, or 40 mg subcutaneous ADA every other week without a loading dose. Ocular parameters were compared between the 2 groups. Results The study included 177 patients (316 affected eyes), of whom 103 received IFX and 74 received ADA . There were no significant baseline differences between treatment groups in main demographic features, previous therapy, or ocular sign severity. After 1 year of therapy, we observed an improvement in all ocular parameters in both groups. However, patients receiving ADA had significantly better outcomes in some parameters, including improvement in anterior chamber inflammation (92.31% versus 78.18% for IFX ; P = 0.06), improvement in vitritis (93.33% versus 78.95% for IFX ; P = 0.04), and best‐corrected visual acuity (mean ± SD 0.81 ± 0.26 versus 0.67 ± 0.34 for IFX ; P = 0.001). A nonsignificant difference was seen for macular thickness (mean ± SD 250.62 ± 36.85 for ADA versus 264.89 ± 59.74 for IFX ; P = 0.15), and improvement in retinal vasculitis was similar between the 2 groups (95% for ADA versus 97% for IFX ; P = 0.28). The drug retention rate was higher in the ADA group (95.24% versus 84.95% for IFX ; P = 0.042). Conclusion Although both IFX and ADA are efficacious in refractory BD ‐related uveitis, ADA appears to be associated with better outcomes than IFX after 1 year of follow‐up.
    Type of Medium: Online Resource
    ISSN: 2326-5191 , 2326-5205
    URL: Issue
    URL: Article
    DOI: 10.1002/art.v71.12
    DOI: 10.1002/art.41026
    RVK:
    XA 10000
    RVK:
    XA 30325
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2754614-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial
    Wiley ; 2020
    In:  Arthritis & Rheumatology Vol. 72, No. 10 ( 2020-10), p. 1607-1620
    Details
    In: Arthritis & Rheumatology, Wiley, Vol. 72, No. 10 ( 2020-10), p. 1607-1620
    Abstract: The SELECT‐EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who were naive for or had limited exposure to methotrexate (MTX). Methods Patients (n = 947) were randomized 1:1:1 to receive once‐daily doses of upadacitinib 15 mg or 30 mg or weekly MTX (7.5–20 mg/week) for 24 weeks. The primary end points were the proportion of patients who met the American College of Rheumatology 50% (ACR50) improvement criteria at week 12, and the proportion in whom a Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP) of 〈 2.6 was achieved at week 24. Data are presented through week 24. Results At baseline, the median disease duration was 0.5 years (range 0–44 years). A total of 840 patients (89%) completed 24 weeks of treatment. The study met both primary end points for upadacitinib 15 mg and 30 mg versus MTX (ACR50 was achieved at week 12 in 52% and 56% of patients, respectively, versus 28% [ P 〈 0.001], and DAS28‐CRP 〈 2.6 was achieved at week 24 in 48% and 50% of patients, respectively, versus 19% [ P 〈 0.001]). Statistically significant and clinically meaningful improvements in multiple patient‐reported outcomes (PROs) were recorded for both upadacitinib doses versus MTX. Overall, 88% of patients receiving upadacitinib 15 mg and 89% of patients receiving 30 mg, respectively, had no radiographic progression (modified total Sharp score ≤0) compared to 78% of those receiving MTX ( P 〈 0.01). Through week 24, the frequency of treatment‐emergent adverse events was similar between the MTX arm (65%) and upadacitinib 15 mg arm (64%), but was slightly higher in the upadacitinib 30 mg arm (71%). Six deaths were reported (2 in the upadacitinib 15 mg arm, 3 in the upadacitinib 30 mg arm, and 1 in the MTX arm). Conclusion Our findings indicate that patients receiving either dose of upadacitinib monotherapy experienced significant improvements in clinical, radiographic, and PROs compared to patients receiving MTX.
    Type of Medium: Online Resource
    ISSN: 2326-5191 , 2326-5205
    URL: Issue
    URL: Article
    DOI: 10.1002/art.v72.10
    DOI: 10.1002/art.41384
    RVK:
    XA 10000
    RVK:
    XA 30325
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2754614-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    TRY plant trait database – enhanced coverage and open access
    Wiley ; 2020
    In:  Global Change Biology Vol. 26, No. 1 ( 2020-01), p. 119-188
    Details
    In: Global Change Biology, Wiley, Vol. 26, No. 1 ( 2020-01), p. 119-188
    Abstract: Plant traits—the morphological, anatomical, physiological, biochemical and phenological characteristics of plants—determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait‐based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits—almost complete coverage for ‘plant growth form’. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait–environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives.
    Type of Medium: Online Resource
    ISSN: 1354-1013 , 1365-2486
    URL: Issue
    URL: Article
    DOI: 10.1111/gcb.v26.1
    DOI: 10.1111/gcb.14904
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2020313-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Immediate one‐piece zirconia implants with/without xenograft in the buccal gap: A 6‐month pre‐clinical study
    Wiley ; 2021
    In:  Clinical Oral Implants Research Vol. 32, No. 5 ( 2021-05), p. 629-640
    Details
    In: Clinical Oral Implants Research, Wiley, Vol. 32, No. 5 ( 2021-05), p. 629-640
    Abstract: To histologically evaluate healing following grafting a xenogenous bone substitute in the buccal gap around the immediately placed one‐piece zirconia implant. Materials and methods The third and fourth premolars (PM3 and PM4) in both quadrants of the mandible of nine Mongrel Hound dogs were used for this experiment. They have been removed, and the recipient sites were prepared. The implants were placed in a lingual position in the socket. In one side of the jaw, the gap between the implant and the socket walls was grafted (test) while no grafting was performed in the contralateral side (control), randomly selected. After 6 months of healing, biopsies were obtained and prepared for histological analysis. Vertical and horizontal measures were recorded in buccal and lingual surface. Results The hard tissue was in a coronal position on the test side compared with the control side. The bone thickness around ZLA (zirconia large‐grit sandblasted and acid‐etched surface) level was larger on the test side. On the test side, the first bone–implant contact and bone crest, at the buccal aspect, were more coronal to ZLA in PM4 while in PM3 the same happened with the bone crest. The width of the buccal bone wall was larger in PM4 than in PM3 at the ZLA level and 1 mm apical to ZLA. Conclusion The placement of a xenograft in the gap between 1‐piece zirconia implant and the buccal wall in dogs modified the process of hard tissue healing, providing additional amount of hard tissue.
    Type of Medium: Online Resource
    ISSN: 0905-7161 , 1600-0501
    URL: Issue
    URL: Article
    DOI: 10.1111/clr.v32.5
    DOI: 10.1111/clr.13735
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2027104-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Immediate placement of one‐piece zirconia implants with or without xenograft into the buccal gap. Soft tissues as secondary outcomes of an experimental in vivo study
    Wiley ; 2023
    In:  Clinical Oral Implants Research Vol. 34, No. 4 ( 2023-04), p. 342-350
    Details
    In: Clinical Oral Implants Research, Wiley, Vol. 34, No. 4 ( 2023-04), p. 342-350
    Abstract: To histologically evaluate soft tissue healing following immediately placed one‐piece zirconia implant and grafting a xenograft into the buccal gap. Materials and Methods The third and fourth premolars (PM3 and PM4) in both quadrants of the mandible of nine dogs were used for this experiment. Those teeth were removed flapless and implants were placed into the distal sockets in a lingual position. In one side of the jaw, the gap between the implant and the socket walls was grafted (test) while no grafting was performed in the contralateral side (control), randomly selected. After 6 months of healing, biopsies were obtained and prepared for histological analysis. Soft tissue measures like supracrestal soft tissue height (STH), length of barrier epithelium (BE), and connective tissue (CTC) were measured at buccal and lingual surfaces. Results The marginal mucosa was in a coronal position on the test side compared with the control side. At the buccal surface, the BE was longer in the test side than in the control side, while the CTC was longer in the control side than in the test side. For the STH (BE + CTC), the difference between the groups was not statistically significant. Conclusion The placement of a xenograft into the gap between a 1‐piece zirconia implant and the buccal wall in dogs modified the process of soft tissue healing, providing less soft tissue recession. The gap size seems to have a modifying effect on the application of this protocol.
    Type of Medium: Online Resource
    ISSN: 0905-7161 , 1600-0501
    URL: Issue
    URL: Article
    DOI: 10.1111/clr.v34.4
    DOI: 10.1111/clr.14044
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2027104-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
    Wiley ; 2022
    In:  Clinical Transplantation Vol. 36, No. 3 ( 2022-03)
    Details
    In: Clinical Transplantation, Wiley, Vol. 36, No. 3 ( 2022-03)
    Abstract: Multicenter, prospective, observational study to compare the relative bioavailability of once‐daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus‐based regimen were included 14 days post‐transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR‐Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (C min /total daily dose [TDD]) vs. PR‐Tac (61% increase; P   〈  .001) with similar C min and 30% lower TDD levels ( P   〈  .0001). The incidence of treatment failure was 3.9% in the LCPT group and 9.0% in the PR‐Tac group ( P = .117). Study discontinuation rates were 6.2% in the LCPT group and 12.4% in the PR‐Tac group ( P = .113). Adverse events, renal function and other complications were comparable between groups. The median accumulated dose of tacrolimus in the LCPT group from day 14 to month 6 was 889 mg. Compared to PR‐Tac, LCPT showed higher relative bioavailability, similar effectiveness at preventing allograft rejection, comparable effect on renal function, safety, adherence, treatment failure and premature discontinuation rates.
    Type of Medium: Online Resource
    ISSN: 0902-0063 , 1399-0012
    URL: Issue
    URL: Article
    DOI: 10.1111/ctr.v36.3
    DOI: 10.1111/ctr.14550
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2739458-X
    detail.hit.zdb_id: 2004801-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...